Please try another search
For the six months ended 30 June 2020, Advanz PharmaCorp Ltd revenues decreased 2% to $261.9M. Net lossdecreased 32% to $35.3M. Revenues reflect ADVANZ PHARMANorth America segment decrease of 10% to $65M, Barbadossegment decrease from $71.5M to $0K, All other countries.segment decrease of 23% to $60.7M, United Kingdom & Jerseysegment decrease of 13% to $106.6M.
Period Ending: | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
---|---|---|---|---|
Total Revenue | 128.74 | 131.87 | 129.99 | 121.96 |
Gross Profit | 79.67 | 86.91 | 86.64 | 79.24 |
Operating Income | -5.41 | -4.35 | 10.6 | -25.62 |
Net Income | -42.02 | -26.59 | -8.69 | -24.6 |
Period Ending: | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
---|---|---|---|---|
Total Assets | 1537.86 | 1503.37 | 1509.39 | 1593.01 |
Total Liabilities | 1605.95 | 1584.74 | 1564.11 | 1577.9 |
Total Equity | -68.09 | -81.37 | -54.72 | 15.11 |
Period Ending: | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | 112.82 | 106.78 | 45.12 | 188.18 |
Cash From Investing Activities | -157.48 | -154.62 | -0.69 | -34.25 |
Cash From Financing Activities | -79.33 | -57.21 | -23.64 | -129.93 |
Net Change in Cash | -120.12 | -111.97 | 5.35 | 36.7 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review